Risk factors for severe immune-related pneumonitis after nivolumab plus ipilimumab therapy for non-small cell lung cancer.
Sumi T, Sekikawa M, Koshino Y, Nagayama D, Nagahisa Y, Matsuura K, Shijubou N, Kamada K, Suzuki K, Ikeda T, Michimata H, Watanabe H, Yamada Y, Osuda K, Tanaka Y, Chiba H.
Sumi T, et al. Among authors: ikeda t.
Thorac Cancer. 2024 Jul;15(20):1572-1581. doi: 10.1111/1759-7714.15385. Epub 2024 Jun 3.
Thorac Cancer. 2024.
PMID: 38828610
Free PMC article.